KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients

被引:1875
作者
Eckardt, Kai-Uwe
Kasiske, Bertram L.
机构
关键词
Guideline; KDIGO; kidney transplant recipient care; immunosuppression; graft monitoring; infectious diseases; cardiovascular disease; malignancy; mineral and bone disorder; hematological complications; hyperuricemia; gout; growth; sexual function; fertility; mental health; HEPATITIS-B-VIRUS; RENAL-ALLOGRAFT RECIPIENTS; POSTTRANSPLANT DIABETES-MELLITUS; QUALITY-OF-LIFE; HEMOLYTIC-UREMIC SYNDROME; I MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; RANDOMIZED CONTROLLED-TRIAL; DELAYED GRAFT FUNCTION; HUMAN GROWTH-HORMONE; EPSTEIN-BARR-VIRUS;
D O I
10.1111/j.1600-6143.2009.02834.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
The 2009 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline on the monitoring, management, and treatment of kidney transplant recipients is intended to assist the practitioner caring for adults and children after kidney transplantation. The guideline development process followed an evidence-based approach, and management recommendations are based on systematic reviews of relevant treatment trials. Critical appraisal of the quality of the evidence and the strength of recommendations followed the Grades of Recommendation Assessment, Development, and Evaluation (GRADE) approach. The guideline makes recommendations for immunosuppression, graft monitoring, as well as prevention and treatment of infection, cardiovascular disease, malignancy, and other complications that are common in kidney transplant recipients, including hematological and bone disorders. Limitations of the evidence, especially on the lack of definitive clinical outcome trials, are discussed and suggestions are provided for future research.
引用
收藏
页码:S1 / S155
页数:155
相关论文
共 931 条
[41]  
[Anonymous], 2009, Kidney Int, VS113, pS1, DOI DOI 10.1038/KI.2009.188
[42]  
[Anonymous], 2006, American Journal of Kidney Disease, V47, pS1
[43]  
[Anonymous], 2008, Kidney Int Suppl, V109, pS1
[44]  
[Anonymous], 2020, USRDS 2020 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States
[45]   The effects of a smoking cessation intervention on 14.5-year mortality - A randomized clinical trial [J].
Anthonisen, NR ;
Skeans, MA ;
Wise, RA ;
Manfreda, J ;
Kanner, RE ;
Connett, JE .
ANNALS OF INTERNAL MEDICINE, 2005, 142 (04) :233-239
[46]   Efficacy and safety of lamivudine in renal transplant patients with chronic hepatitis B [J].
Antoine, C ;
Landau, A ;
Menoyo, V ;
Duong, JP ;
Duboust, A ;
Glotz, D .
TRANSPLANTATION PROCEEDINGS, 2000, 32 (02) :384-385
[47]   Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs [J].
Araki, M ;
Flechner, SM ;
Ismail, HR ;
Flechner, LM ;
Zhou, LM ;
Derweesh, IH ;
Goldfarb, D ;
Modlin, C ;
Novick, AC ;
Faiman, C .
TRANSPLANTATION, 2006, 81 (03) :335-341
[48]   Patient survival after renal transplantation; more than 25 years follow-up [J].
Arend, SM ;
Mallat, MJK ;
Westendorp, RJW ;
vanderwoude, FJ ;
vanEs, LA .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (08) :1672-1679
[49]  
Armenti Vincent T, 2006, Clin Transpl, P57
[50]  
Armenti Vincent T, 2004, Clin Transpl, P103